Literature DB >> 20227407

Ex vivo delivery of GDNF maintains motor function and prevents neuronal loss in a transgenic mouse model of Huntington's disease.

Allison D Ebert1, Amelia E Barber, Brittany M Heins, Clive N Svendsen.   

Abstract

Huntington's disease (HD) is an autosomal dominant disorder caused by expansion of polyglutamine repeats in the huntingtin gene leading to loss of striatal and cortical neurons followed by deficits in cognition and choreic movements. Growth factor delivery to the brain has shown promise in various models of neurodegenerative diseases, including HD, by reducing neuronal death and thus limiting motor impairment. Here we used mouse neural progenitor cells (mNPCs) as growth factor delivery vehicles in the N171-82Q transgenic mouse model of HD. mNPCs derived from the developing mouse striatum were isolated and infected with lentivirus expressing either glial cell line-derived neurotrophic factor (GDNF) or green fluorescent protein (GFP). Next, mNPCs(GDNF) or mNPCs(GFP) were transplanted bilaterally into the striatum of pre-symptomatic N171-82Q mice. We found that mNPCs(GDNF), but not mNPCs(GFP), maintained rotarod function and increased striatal neuron survival out to 3months post-transplantation. Importantly, histological analysis showed GDNF expression through the duration of the experiment. Our data show that mNPCs(GDNF) can survive transplantation, secrete GDNF for several weeks and are able to maintain motor function in this model of HD. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20227407     DOI: 10.1016/j.expneurol.2010.03.005

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  31 in total

Review 1.  Experimental surgical therapies for Huntington's disease.

Authors:  Jelle Demeestere; Wim Vandenberghe
Journal:  CNS Neurosci Ther       Date:  2010-12-28       Impact factor: 5.243

Review 2.  The importance of integrating basic and clinical research toward the development of new therapies for Huntington disease.

Authors:  Ignacio Munoz-Sanjuan; Gillian P Bates
Journal:  J Clin Invest       Date:  2011-02-01       Impact factor: 14.808

Review 3.  Current challenges for the advancement of neural stem cell biology and transplantation research.

Authors:  Kristien Reekmans; Jelle Praet; Jasmijn Daans; Veerle Reumers; Patrick Pauwels; Annemie Van der Linden; Zwi N Berneman; Peter Ponsaerts
Journal:  Stem Cell Rev Rep       Date:  2012-03       Impact factor: 5.739

Review 4.  Concise review: Can stem cells be used to treat or model Alzheimer's disease?

Authors:  Wesley W Chen; Mathew Blurton-Jones
Journal:  Stem Cells       Date:  2012-12       Impact factor: 6.277

Review 5.  Gene therapy in mouse models of huntington disease.

Authors:  Amber L Southwell; Paul H Patterson
Journal:  Neuroscientist       Date:  2011-04       Impact factor: 7.519

Review 6.  Neural stem cell therapy for neurodegenerative disorders: The role of neurotrophic support.

Authors:  Samuel E Marsh; Mathew Blurton-Jones
Journal:  Neurochem Int       Date:  2017-02-20       Impact factor: 3.921

Review 7.  Therapeutic effects of stem cells in rodent models of Huntington's disease: Review and electrophysiological findings.

Authors:  Sandra M Holley; Talia Kamdjou; Jack C Reidling; Brian Fury; Dane Coleal-Bergum; Gerhard Bauer; Leslie M Thompson; Michael S Levine; Carlos Cepeda
Journal:  CNS Neurosci Ther       Date:  2018-03-06       Impact factor: 5.243

8.  Interneuron progenitors attenuate the power of acute focal ictal discharges.

Authors:  Estanislao De la Cruz; Mingrui Zhao; Lihua Guo; Hongtao Ma; Stewart A Anderson; Theodore H Schwartz
Journal:  Neurotherapeutics       Date:  2011-10       Impact factor: 7.620

9.  Interaction between nonviral reprogrammed fibroblast stem cells and trophic factors for brain repair.

Authors:  G Liu; H Anisman; J Bobyn; S Hayley
Journal:  Mol Neurobiol       Date:  2014-03-28       Impact factor: 5.590

Review 10.  Modeling Huntington's disease with induced pluripotent stem cells.

Authors:  Julia A Kaye; Steven Finkbeiner
Journal:  Mol Cell Neurosci       Date:  2013-02-28       Impact factor: 4.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.